Article Details
Retrieved on: 2022-07-29 17:18:49
Tags for this article:
Click the tags to see associated articles and topics
Excerpt
Wedbush has a “Initiates” rating on the stock. The consensus estimate for Vor Biopharma's current full-year earnings is ($2.73) per share. Wedbush ...
Article found on: www.defenseworld.net
This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here